Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | KLK8 | O60259 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025497 | 0.84 | ANPEP (0.36) | KLK1ELANEANPEPLAP3 | |
| SCHEMBL27554232 | 0.84 | ANPEP (0.36) | KLK1ELANEANPEPLAP3 | |
| SCHEMBL857081 | 0.71 | ELANE (0.48) | KLK1ELANETP53PRTN3KMT2A | |
| SCHEMBL1812174 | 0.70 | ELANE (0.45) | ELANEPRTN3 | |
| SCHEMBL15721086 | 0.68 | KMT2A (0.44) | ELANETP53PRTN3KMT2A | |
| SCHEMBL12502213 | 0.68 | ELANE (0.41) | ELANEPRTN3PLAUALDH1A1 | |
| SCHEMBL8519322 | 0.68 | TSHR (0.53) | ELANEKMT2AANPEPLAP3 | |
| SCHEMBL4277278 | 0.68 | ENPP2 (0.34) | ELANETP53KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3971071 | 0.67 | NPC1 (0.42) | KLK1ELANETP53PRTN3KMT2A | |
| SCHEMBL1811535 | 0.67 | GAA (0.42) | ELANEKMT2AF2PLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | KLK1 4829/4885ELANE 3126/4885TP53 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.